 | |
| Clinical data | |
|---|---|
| Other names | Pruxelutamide; GT-0918 |
| Routes of administration | By mouth |
| Drug class | Nonsteroidal antiandrogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H19F4N5O2S |
| Molar mass | 517.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Proxalutamide (developmental code nameGT-0918) is anonsteroidal antiandrogen (NSAA) – specifically, aselective high-affinitysilentantagonist of theandrogen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment ofCOVID-19,prostate cancer, andbreast cancer.[1][2][3][4][5] It was approved inParaguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.[1]
Proxalutamide is in phase III studies formCRPC as monotherapy and in combination withabiraterone. In the United States, it is in phase II study as monotherapy for mCRPC.[6][7]
Proxalutamide is in phase Ic clinical trial in China.[1][8]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
